ClinicalTrials.gg

Program

recaticimab

Also written as “SHR-1209”, “SHR-1209 single-site subcutaneous injection” and “SHR-1209 multiple-site subcutaneous injections”.

Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Hyperlipoproteinemia Type II, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Mar 31, 20217 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine70 open or runningphase 3since Mar 31, 2021Aug 6, 2018none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 6, 2018First study: phase 1 study in HypercholesterolemiaFirst studyNCT03634436 · 32 enrolled · China
  2. May 4, 2019Phase 2 study in HyperlipidemiasNCT03944109 · 110 enrolled · China
  3. Jun 29, 2020Phase 2 study in Hyperlipoproteinemia Type IINCT04455581 · 8 enrolled
  4. Mar 31, 2021Phase 3 study in Hyperlipoproteinemia Type VNCT04849000 · 709 enrolled · China
  5. Apr 2, 2021Phase 3 study in Primary HypercholesterolemiaNCT04844125 · 144 enrolled · China
  6. May 7, 2022Phase 1 study in HypercholesterolemiaNCT05370950 · 159 enrolled · China
  7. Jan 7, 2025Phase 1 study in HypercholesterolemiaNCT06837077 · 49 enrolled · China

TargetBeta

PCSK9 →read by rule
“Recaticimab (SHR-1209) injection, a fully human monoclonal antibody targeting PCSK9.”study text, by rule · the study

Other programs on PCSK9

ProgramCompanyFurthest phaseStudies
alirocumabruleSanofiphase 448
evolocumabruleAmgenphase 445
inclisiranruleNovartisphase 437
lerodalcibeprulelib-therapeutics-llcphase 314
tafolecimabruleInnovent Biologicsphase 38
QLC7401ruleQilu Pharmaceuticalphase 35
SAL003ruleShenzhen Salubris Pharmaceuticalsphase 33
VERVE-102Eli Lillyphase 22
DNV001rulehangzhou-dinovate-biotech-co-ltdphase 21
RBD7022ruleQilu Pharmaceuticalphase 12

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06837077Hypercholesterolemia · China1CompletedNov 1, 202549
NCT05370950Hypercholesterolemia · China1CompletedDec 31, 2022159
NCT04844125Primary Hypercholesterolemia · China3CompletedAug 12, 2022144
NCT04849000Hyperlipoproteinemia Type V · China3CompletedJun 21, 2022709
NCT04455581Hyperlipoproteinemia Type II2UNKNOWNJun 30, 20218
NCT03944109Hyperlipidemias · China2CompletedDec 22, 2020110
NCT03634436Hypercholesterolemia · China1CompletedMay 28, 201932

How it is read

Names in the registry

  • “SHR-1209”, 6 entries
  • “SHR-1209 single-site subcutaneous injection”, 1 entry
  • “SHR-1209 multiple-site subcutaneous injections”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.